The FDA has approved Sancuso (granisetron transdermal patch, from ProStrakan) for the prevention of chemotherapy-induced nausea and vomiting (CINV).

This approval was based on a Phase III double-blind study that showed Sancuso was as effective as oral granisetron in achieving complete CINV control. Complete control was defined as no vomiting and/or retching, no more than mild nausea, and no rescue medication from the first dose of Sancuso until 24 hours after the last day of chemotherapy.

For more information call (908) 234-1096 or visit